Gt biopharma announces updated positive safety data from phase 1 gtb-3550 monotherapy trike™ trial an investigational immunotherapy for refractory cancers to be presented at esmo congress 2021

Beverly hills, calif., sept. 15, 2021 /prnewswire/ -- gt biopharma, inc. (the "company") (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike protein biologic technology platform, today announced that jeffrey miller, md, university of minnesota medical school, professor of medicine, division of hematology, oncology and transportation will present a mini-oral presentation at the european society for medical oncology (esmo) congress 2021 to be held virtually september 16-21.
GTBP Ratings Summary
GTBP Quant Ranking